Program
risvutatug rezetecan
Also written as “HS-20093”, “HS-20093 for Injection” and “Risvutatug rezetecan (Ris-Rez)”.
In GlaxoSmithKline’s pipeline, ADC targeting B7-H3
. Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Osteosarcoma · Neoplasms · Prostatic Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Groupits history only | 2117 open or running | phase 3since Jul 6, 2024 | Feb 18, 2022 | Dec 30, 2026phase 1 · NCT06699576 |
| GlaxoSmithKlineits history only | 88 open or running | phase 3since Jul 30, 2025 | Mar 3, 2022 | Nov 5, 2027phase 3 · NCT07099898 |
| Jiangsu HengRui Medicine | 11 open or running | phase 2since Nov 13, 2025 | Nov 13, 2025 | Dec 2028phase 2 · NCT07230106 |
- Named in GlaxoSmithKline’s own pipeline as
risvutatug rezetecan GSK5764227
, phase 3, as of Sep 30, 2026 (source). - Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-20093 (B7-H3 ADC)
, phase 3, as of Aug 26, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseGSK licensed it from Hansoh, for everywhere outside mainland China, Hong Kong, Macau and Taiwan.Announced Dec 20, 2023 · Source: GSK, Dec 20, 2023
How Jiangsu HengRui Medicine relates to it is not in the registry or these sources.
History and studies of Jiangsu HengRui Medicine only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 20, 2023GSK licensed it from HansohLicenseEverywhere outside mainland China, Hong Kong, Macau and Taiwan · announced · GSK
- Jul 10, 2025Named risvutatug rezetecanINNProposed as its International Nonproprietary Name in WHO's List 133 · before, HS-20093, GSK5764227
- Nov 13, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT07230106 · 218 planned · China
Ahead
- Dec 2028Primary completion: phase 2 study in Prostatic NeoplasmsNCT07230106
TargetBeta
“ADC targeting B7-H3”the company's pipeline, read by Claude · source
“B7-H3 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of risvutatug, a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the T-cell checkpoint ligand B7-homologue 3 (B7-H3, CD276) covalently ”NCIt, by rule
Other programs on CD276
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ifinatamab deruxtecan | Merck | phase 3 | 16 |
| tambotatug pelitecan | MediLink Therapeutics (Suzhou) | phase 3 | 13 |
| Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 | CSPC Pharmaceutical Group | phase 3 | 6 |
| Anti-B7-H3 Antibody-drug Conjugate MHB088Crule | Minghui Pharmaceutical | phase 3 | 4 |
| Elfetabart Drozuntecanrule | BioNTech | phase 3 | 3 |
| Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101rule | tj-biopharma-co-ltd | phase 3 | 3 |
| Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01rule | radiopharm-theranostics-ltd | phase 2 | 1 |
| Autologous Anti-B7-H3 CAR T-cells BCB-276rule | brainchild-bio-inc | phase 2 | 1 |
| Anti-B7-H3/CD28 Bispecific Antibody XmAb808rule | Xencor | phase 1 | 2 |
| Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034rule | ideaya-biosciences | phase 1 | 1 |
| Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001rule | neok-bio-inc | phase 1 | 1 |
| HLX316 | Fosun Pharma | phase 1 | 1 |
Studies
The one study Jiangsu HengRui Medicine leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07230106Prostatic Neoplasms · China | 2 | Recruiting | Dec 2028 | 218 |
How it is read
Names in the registry
- “HS-20093”, 15 entries
- “HS-20093 for Injection”, 4 entries
- “Risvutatug rezetecan (Ris-Rez)”, 2 entries
- “GSK5764227”, 2 entries
- “Ris-Rez”, 2 entries
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 6 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Osteosarcoma, 3 studies
- Neoplasms, 3 studies
- Prostatic Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.